These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3487380)

  • 1. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
    Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.
    Dullens HF; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 23(2):113-8. PubMed ID: 3536093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.
    De Weger RA; Wilbrink B; Moberts RM; Mans D; Oskam R; Den Otter W
    Cancer Immunol Immunother; 1987; 24(1):25-36. PubMed ID: 3493070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine macrophage cytotoxicity induced by mastocytoma cells, cell-free mastocytoma exudates, and extracts.
    Dullens HF; Den Otter W
    Immunopharmacology; 1981 Sep; 3(3):241-51. PubMed ID: 6796544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of tumor cells after injection into immunized hosts compared with the eradication of tumor cells after transfer of immune peritoneal exudates into tumor-bearing recipients.
    Den Otter W; De Groot JW; Dullens HF
    Cancer Immunol Immunother; 1983; 16(2):72-6. PubMed ID: 6559103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens.
    Bergers JJ; Den Otter W; Dullens HF; De Groot JW; Steerenberg PA; Filius PM; Crommelin DJ
    Int J Cancer; 1994 Mar; 56(5):721-6. PubMed ID: 8314349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of correlation between in vivo peroxidatic activity patterns and tumoricidal activity in vitro of peritoneal macrophages after intraperitoneal immunization with tumor cells.
    Dullens HF; van Walraven R; Klomberg M; Rademakers LP; de Goey IC; den Otter W
    Immunobiology; 1988 Jul; 177(3):293-304. PubMed ID: 3169842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with antibody-coated immune and hyperimmune peritoneal cells in a murine lymphoma system.
    Dullens HF; De Weger RA; Woutersen RA; Den Otter W
    J Natl Cancer Inst; 1975 Jan; 54(1):77-82. PubMed ID: 1167595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
    Maas RA; Becker MJ; Weimar IS; De Nooy JC; Dullens HF; Den Otter WD
    Immunobiology; 1993 Jul; 188(3):281-92. PubMed ID: 7901148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.
    Jiang H; Stewart CA; Fast DJ; Leu RW
    J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
    Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
    Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytolytic activity by combined populations of peritoneal T lymphocytes and macrophages during the L5178Y cell tumor-dormant state in DBA/2 mice.
    Robinson MK; Wheelock EF
    Cell Immunol; 1982 Nov; 73(2):230-46. PubMed ID: 6984360
    [No Abstract]   [Full Text] [Related]  

  • 16. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL
    Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte subpopulations elicited by a nontumorigenic variant of B16 melanoma: their role in direct rejection of the melanoma and in prevention of tumorigenesis in Winn assays.
    Calvelli TA; Freedman VH; Silverstein SC; Silagi S
    J Exp Med; 1982 Dec; 156(6):1723-38. PubMed ID: 6983560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.
    Papanastasiou M; Baxevanis CN; Papamichail M
    Cancer Immunol Immunother; 1992; 35(2):145-50. PubMed ID: 1596938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cellular cytotoxicity against tumor cells. I. Cultivated bone marrow-derived macrophages kill tumor targets.
    Lohmann-Matthes ML; Domzig W; Taskov H
    Eur J Immunol; 1979 Apr; 9(4):261-6. PubMed ID: 467489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.